Co-Chair
Renata
Fialho de Oliveira
Co-Chair
Anne Walsh
Healthcare and Life Sciences Law Committee
The Healthcare and Life Sciences Law Committee addresses legal issues in the healthcare and life sciences sectors, such as medicine, intellectual property, biotech, bioethics, regulatory matters, and scientific developments. With a dynamic, diverse, and growing membership, the Committee fosters collaboration to tackle industry challenges, such as increased competition and regulatory changes.
We provide a platform for discussion, sharing knowledge, and updating members on key developments. Through conferences, seminars, and global events, the Committee promotes professional growth, enabling members to benefit from advanced practices in well-established jurisdictions while supporting those new to this field.
Why join the Healthcare and Life Sciences Law Committee
We provide a platform for discussion, sharing knowledge, and updating members on key developments. Through conferences, seminars, and global events, the Committee promotes professional growth, enabling members to benefit from advanced practices in well-established jurisdictions while supporting those new to this field.
Forthcoming conferences and webinars View All Conferences
Licensing with strategic partners in life sciences
12 Jan 2026 1600 - 1700 GMT
Webinar
12th Annual IBA World Life Sciences Conference
03 Jun - 05 Jun 2026
Lisbon , Portugal
IBA Annual Conference Copenhagen 2026
04 Oct - 09 Oct 2026
Copenhagen , Denmark
Projects
IBA Healthcare and Life Sciences Law Committee annual global surveys
Each year the Healthcare and Life Sciences Law Committee has produced a new comparative legal guide covering a highly relevant topic in over 50 countries, comprising responses to a survey. This guide is intended to offer practitioners and industry users easy access to the relevant applicable rules. In 2025, the Committee looked at healthcare financing and reimbursement. In 2024, the Committee summarised the requirements for promoting pharmaceutical and medical devices. In 2023, the Committee addressed questions related to telemedicine.
Publications
The legal landscape for the use of AI in drug discovery in Indonesia, Thailand and Vietnam
Artificial intelligence (AI) is reshaping the global pharmaceutical industry through its expanding role in drug discovery. From identifying novel compounds to enhancing clinical trial processes, its influence is increasingly evident in Southeast Asian countries, where the intellectual property (IP) regime faces new challenges posed by AI-generated pharmaceutical inventions. For legal practitioners, providing sound counsel in this evolving field requires a deep understanding of the IP framework and the uncertainties that surround it in Southeast Asia.
Released on Dec 08, 2025
The legal landscape for the provision of home respiratory care in Portugal
This article analyses the legal framework on the provision of home respiratory care in Portugal. It addresses the evolution of the applicable legal framework, the benefits of competition among providers and national coverage, with references to the contracting model for these services and its advantages.
Released on Dec 04, 2025
AI and digital health in Brazil: balancing innovation and regulation
Brazil’s digital health offering is rapidly evolving. The Brazilian National Digital Health Strategy 2020–2028 (Estratégia de Saúde Digital or ESD) and the National Health Data Network (Rede Nacional de Dados em Saúde or RNDS) lay down the foundations for interoperability, while the Brazilian Artificial Intelligence (AI) Plan 2024–2028 (Plano Brasileiro de Inteligência Artificial or PBIA) steers the health-focused AI initiatives. Despite having no AI-specific statute and the ongoing debate over Bill No. 2,338/2023, the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária or ANVISA) regulates AI-enabled software as a medical device (SaMD) according to the applicable risk-based rules, including Resolutions 657/2022, 751/2022 and 830/2023. Privacy governance, led by the National Data Protection Authority (Agência Nacional de Proteção de Dados or ANPD) pursuant to the General Personal Data Protection Law (Lei Geral de Proteção de Dados Pessoais or LGPD), shapes dataset access and model transparency. This article maps the relevant obligations, interoperability challenges and priorities for the creation of a safety- and innovation-balanced regulatory framework in Brazil.
Released on Dec 04, 2025
Beyond borders 2025: the top five considerations on the road to success in cross-border life sciences M&A
The pharmaceutical industry is entering a defining era of transformation. As the complexity of therapeutics increases, from antibody–drug conjugates to trispecific T-cell engagers, so does the need for sophisticated dealmaking strategies. At the same time, factors such as geopolitical uncertainty, artificial intelligence (AI)-driven innovation and the impending patent cliff are pushing life sciences companies to rethink where and how they invest. This article explores five key considerations that are shaping success in cross-border life sciences M&A, with examples from recent transactions that illustrate these shifting trends.
Released on Dec 04, 2025
Subcommittees and other groups
The Healthcare and Life Sciences Law Committee also coordinates the activities of the following subcommittees/working groups.
- Healthcare and Life Sciences Law Committee Advisory Board
Join us on LinkedIn
If you are a member of the Healthcare and Life Sciences Law Committee, for additional networking opportunities, programs, interviews with fellow members and tips all exclusive to members, join our LinkedIn page at: https://www.linkedin.com/groups/9166617/.